NEW YORK, January 18, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Robinson Brothers, one of the UK’s largest independent chemical manufacturers, is now using its revolutionary portable Intelligent Fingerprinting Drug Screening System to support its drug and alcohol testing policy.
Robinson Brothers runs a 24×7 chemical manufacturing operation at its West Bromwich facility. The company’s HR team found that its previously outsourced drug testing provision was not responsive enough to support its requirements. Adopting the Intelligent Fingerprinting Drug Screening System will allow Robinson Brothers to bring drug testing in-house, with its portability, flexibility and ease-of-use enabling random testing across the business and for cause tests wherever and whenever needed.
“We previously used an external provider to carry out urine-based drug testing on a random basis. This was not only unhygienic and intrusive for everyone involved, but also invariably led to productivity delays as people sat around waiting to be tested,” explained Steve Doyle, Human Resources Manager at Robinson Brothers. “However, when we found out about fingerprint-based drug screening, we immediately saw how we could conduct our own testing in-house and in a much less invasive way. Additionally, because the system is so portable and easy to use, it works as an on-site visual deterrent and provides a great way of supporting our Drug and Alcohol Policy across the business.”
“From our initial cost analysis, we see fingerprint-based drug screening as highly cost-effective,” added Steve. “Including the initial capital costs of the DSR-Plus drug screening cartridge reader, we estimate that Intelligent Fingerprinting will allow us to conduct the same volume of tests at around half the cost. This, of course, becomes even more competitive as capital costs are written down.”
“As a 24/7 manufacturing operation, Robinson Brothers clearly appreciated the flexibility that sweat-based drug testing provides, giving the HR team the ability to screen employees whenever they need to,” added Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. “What’s clear is that our portable, non-invasive system takes the complexity out of workplace drug testing and is increasingly replacing traditional workplace testing methods using urine and saliva.”
An introductory video demonstrating fingerprint-based drug testing in action is available here.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the “Company”) (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: www.ibs.inc
About Robinson Brothers
Founded in 1869, Robinson Brothers is one of the UK’s largest independent chemical manufacturers, offering contract research and manufacture as well as a significant number of its own in-house developed molecules. The company operates across a number of markets, including pharmaceutical, agrochemical, flavour and flagrance, personal care, adhesives and coatings, and specialised polymer additives. Core competencies include high-pressure hydrogenation, carbon disulfide chemistry, amination, bromination, thiolation, heterocyclic chemistry, dehydrogenation and oxidation. Robinson Brothers also offers its own Robac Technology range that focuses specifically on chemicals used in dry and wet rubber applications, plus additional polymer additives.
For more information, visit www.robinsonbrothers.co.uk
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Cheryl Billson, Comma Communications
+44 (0)7791 720460